Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for TransMedics (TMDX) over the last 6 years, with Q3 2025 value amounting to $0.66.

  • TransMedics' EPS (Weighted Average and Diluted) rose 45000.0% to $0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.48, marking a year-over-year increase of 16382.98%. This contributed to the annual value of $1.01 for FY2024, which is 23116.88% up from last year.
  • According to the latest figures from Q3 2025, TransMedics' EPS (Weighted Average and Diluted) is $0.66, which was up 45000.0% from $0.92 recorded in Q2 2025.
  • TransMedics' 5-year EPS (Weighted Average and Diluted) high stood at $0.92 for Q2 2025, and its period low was -$0.78 during Q3 2023.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.08 (2023), whereas its average is -$0.02.
  • In the last 5 years, TransMedics' EPS (Weighted Average and Diluted) plummeted by 21200.0% in 2023 and then soared by 126666.67% in 2024.
  • TransMedics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.46 in 2021, then soared by 56.52% to -$0.2 in 2022, then skyrocketed by 160.0% to $0.12 in 2023, then skyrocketed by 66.67% to $0.2 in 2024, then surged by 230.0% to $0.66 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $0.66 for Q3 2025, versus $0.92 for Q2 2025 and $0.7 for Q1 2025.